Drugs / AZD2287
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06879041 | Mar 2025 → Apr 2029 expected | castration-resistant prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06267729 | Mar 2024 → Nov 2026 expected | metastatic prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07590934 Background | Jun 2026 → Sep 2029 expected | metastatic prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2287 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06267729 ↗ |
| Modality | Diagnostic / imaging agent | “a novel imaging agent for STEAP2” NCT06267729 ↗ |
| Route | Intravenous | “administered as an IV injection” NCT07590934 ↗ |
| Target | STEAP2 | “a novel imaging agent for STEAP2” NCT06267729 ↗ |